168 related articles for article (PubMed ID: 28292893)
1. Small molecule selectively suppresses MYC transcription in cancer cells.
Bouvard C; Lim SM; Ludka J; Yazdani N; Woods AK; Chatterjee AK; Schultz PG; Zhu S
Proc Natl Acad Sci U S A; 2017 Mar; 114(13):3497-3502. PubMed ID: 28292893
[TBL] [Abstract][Full Text] [Related]
2. A small molecule primes embryonic stem cells for differentiation.
Zhu S; Wurdak H; Wang J; Lyssiotis CA; Peters EC; Cho CY; Wu X; Schultz PG
Cell Stem Cell; 2009 May; 4(5):416-26. PubMed ID: 19427291
[TBL] [Abstract][Full Text] [Related]
3. Design, Synthesis, and Evaluation of Isaindigotone Derivatives To Downregulate c-myc Transcription via Disrupting the Interaction of NM23-H2 with G-Quadruplex.
Shan C; Yan JW; Wang YQ; Che T; Huang ZL; Chen AC; Yao PF; Tan JH; Li D; Ou TM; Gu LQ; Huang ZS
J Med Chem; 2017 Feb; 60(4):1292-1308. PubMed ID: 28128954
[TBL] [Abstract][Full Text] [Related]
4. Nucleoside diphosphate kinase B promotes osteosarcoma proliferation through c-Myc.
Li S; Hu T; Yuan T; Cheng D; Yang Q
Cancer Biol Ther; 2018 Jul; 19(7):565-572. PubMed ID: 29630434
[TBL] [Abstract][Full Text] [Related]
5. Chemical intervention of the NM23-H2 transcriptional programme on c-MYC via a novel small molecule.
Shan C; Lin J; Hou JQ; Liu HY; Chen SB; Chen AC; Ou TM; Tan JH; Li D; Gu LQ; Huang ZS
Nucleic Acids Res; 2015 Aug; 43(14):6677-91. PubMed ID: 26117539
[TBL] [Abstract][Full Text] [Related]
6. Design, Synthesis, and Evaluation of New Selective NM23-H2 Binders as c-MYC Transcription Inhibitors via Disruption of the NM23-H2/G-Quadruplex Interaction.
Wang YQ; Huang ZL; Chen SB; Wang CX; Shan C; Yin QK; Ou TM; Li D; Gu LQ; Tan JH; Huang ZS
J Med Chem; 2017 Aug; 60(16):6924-6941. PubMed ID: 28714689
[TBL] [Abstract][Full Text] [Related]
7. PIWIL2 induces c-Myc expression by interacting with NME2 and regulates c-Myc-mediated tumor cell proliferation.
Yao Y; Li C; Zhou X; Zhang Y; Lu Y; Chen J; Zheng X; Tao D; Liu Y; Ma Y
Oncotarget; 2014 Sep; 5(18):8466-77. PubMed ID: 25193865
[TBL] [Abstract][Full Text] [Related]
8. A reciprocal regulatory circuit between CD44 and FGFR2 via c-myc controls gastric cancer cell growth.
Park J; Kim SY; Kim HJ; Kim KM; Choi EY; Kang MS
Oncotarget; 2016 May; 7(19):28670-83. PubMed ID: 27107424
[TBL] [Abstract][Full Text] [Related]
9. Non-immunosuppressive triazole-based small molecule induces anticancer activity against human hormone-refractory prostate cancers: the role in inhibition of PI3K/AKT/mTOR and c-Myc signaling pathways.
Leu WJ; Swain ShP; Chan SH; Hsu JL; Liu SP; Chan ML; Yu CC; Hsu LC; Chou YL; Chang WL; Hou DR; Guh JH
Oncotarget; 2016 Nov; 7(47):76995-77009. PubMed ID: 27769069
[TBL] [Abstract][Full Text] [Related]
10. Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors.
Marampon F; Ciccarelli C; Zani BM
Mol Cancer; 2006 Aug; 5():31. PubMed ID: 16899113
[TBL] [Abstract][Full Text] [Related]
11. Reversible linkage of two distinct small molecule inhibitors of Myc generates a dimeric inhibitor with improved potency that is active in myc over-expressing cancer cell lines.
Wanner J; Romashko D; Werner DS; May EW; Peng Y; Schulz R; Foreman KW; Russo S; Arnold LD; Pingle M; Bergstrom DE; Barany F; Thomson S
PLoS One; 2015; 10(4):e0121793. PubMed ID: 25875098
[TBL] [Abstract][Full Text] [Related]
12. Requirement of transcription factor NME2 for the maintenance of the stemness of gastric cancer stem-like cells.
Qi Y; Wei J; Zhang X
Cell Death Dis; 2021 Oct; 12(10):924. PubMed ID: 34628473
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of cIAP1 as a strategy for targeting c-MYC-driven oncogenic activity.
Li H; Fang Y; Niu C; Cao H; Mi T; Zhu H; Yuan J; Zhu J
Proc Natl Acad Sci U S A; 2018 Oct; 115(40):E9317-E9324. PubMed ID: 30181285
[TBL] [Abstract][Full Text] [Related]
14. miR-494 acts as an anti-oncogene in gastric carcinoma by targeting c-myc.
He W; Li Y; Chen X; Lu L; Tang B; Wang Z; Pan Y; Cai S; He Y; Ke Z
J Gastroenterol Hepatol; 2014; 29(7):1427-34. PubMed ID: 24612089
[TBL] [Abstract][Full Text] [Related]
15. Metabolic targeting of oncogene MYC by selective activation of the proton-coupled monocarboxylate family of transporters.
Gan L; Xiu R; Ren P; Yue M; Su H; Guo G; Xiao D; Yu J; Jiang H; Liu H; Hu G; Qing G
Oncogene; 2016 Jun; 35(23):3037-48. PubMed ID: 26434591
[TBL] [Abstract][Full Text] [Related]
16. The synthetic molecule stauprimide impairs cell growth and migration in triple-negative breast cancer.
Carrillo P; Bernal M; Téllez-Quijorna C; Marrero AD; Vidal I; Castilla L; Caro C; Domínguez A; García-Martín ML; Quesada AR; Medina MA; Martínez-Poveda B
Biomed Pharmacother; 2023 Feb; 158():114070. PubMed ID: 36526536
[TBL] [Abstract][Full Text] [Related]
17. Identification of synthetic lethality of PRKDC in MYC-dependent human cancers by pooled shRNA screening.
Zhou Z; Patel M; Ng N; Hsieh MH; Orth AP; Walker JR; Batalov S; Harris JL; Liu J
BMC Cancer; 2014 Dec; 14():944. PubMed ID: 25495526
[TBL] [Abstract][Full Text] [Related]
18. Inhibiting MYC binding to the E-box DNA motif by ME47 decreases tumour xenograft growth.
Lustig LC; Dingar D; Tu WB; Lourenco C; Kalkat M; Inamoto I; Ponzielli R; Chan WCW; Shin JA; Penn LZ
Oncogene; 2017 Dec; 36(49):6830-6837. PubMed ID: 28806396
[TBL] [Abstract][Full Text] [Related]
19. Gene expression profiling of MYC-driven tumor signatures in porcine liver stem cells by transcriptome sequencing.
Aravalli RN; Talbot NC; Steer CJ
World J Gastroenterol; 2015 Feb; 21(7):2011-29. PubMed ID: 25717234
[TBL] [Abstract][Full Text] [Related]
20. ERK-dependent downregulation of Skp2 reduces Myc activity with HGF, leading to inhibition of cell proliferation through a decrease in Id1 expression.
Li X; Bian Y; Takizawa Y; Hashimoto T; Ikoma T; Tanaka J; Kitamura N; Inagaki Y; Komada M; Tanaka T
Mol Cancer Res; 2013 Nov; 11(11):1437-47. PubMed ID: 24177224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
